Novo Nordisk provides patient assistance for those who qualify
Putting orforglipron in context Because obesity therapies are evolving rapidly in a market dominated by injectables since semaglutides weight-loss approval in 2021, it is helpful to view orforglipron alongside established and emerging incretin-based drugs
Inside the ReEdt Expert Panel at Renna Recently, we had the pleasure of taking part in the first ReEdt Expert Panel , an evening exploring the growing impact of GLP-1 medications on metabolic health, physical appearance, and aesthetic medicine
For a detailed comparison, retatrutide versus semaglutide breaks down the differences, while the retatrutide dosage chart for weight loss and retatrutide dose complete guide provide dosing specifics
Findings presented at the SCAI 2026 Scientific Sessions & CAIC-ACCI Summit in Montreal in April indicate that GLP-1 medications containing tirzepatide (Mounjaro and Zepbound) may help lower the risk of heart problems in people with obesity undergoing certain heart procedures